Heidelberg, Germany, and Shanghai, China – May 27, 2025 – Full-Life Technologies ("Full-Life", the "Company"), a fully integrated clinical-stage global radiotherapeutics company, today announced that the Company will participate ASCO (“American Society of Clinical Oncology”) 2025 annual meeting and deliver a poster presentation on June 2nd, 2025, 9:00 AM CT.

Heidelberg, Germany and Shanghai, China – May 8, 2025 – Full-Life Technologies ("Full-Life", the "Company"), a fully integrated clinical-stage global radiotherapeutics company, today announced the appointment of Debora Barton, MD, as Chief Medical Officer.

Heidelberg, Germany, and Shanghai, China – April 22, 2025 – Full-Life Technologies ("Full-Life", the "Company"), a fully integrated clinical-stage global radiotherapeutics company, today announced that the Company will present research on FL-031 and FL-801 at AACR 2025 annual meeting. Dr. Fa Liu, Chief Scientific Officer, will give two poster presentations on April 27, 2025, 2:00 PM CDT.

Heidelberg, Germany, Gembloux, Belgium, and Shanghai, China — December 19, 2024 — Full-Life Technologies, a clinical-stage, fully integrated global radiotherapeutics company, today announced that Julie Wu, President & Chief Financial Officer, Dr. Fa Liu, Chief Scientific Officer and Oliver Froescheis, Senior Vice President of Corporate Development will participate in the 43rd Annual J.P. Morgan Healthcare Conference being held January 13-16, 2025 in San Francisco, California, USA, and host meetings.

Gembloux, Belgium, and Shanghai, China – December 5, 2024 – Full-Life Technologies ("Full-Life", the "Company"), a fully integrated global radiotherapeutics company, today announced the progress of its radioisotope manufacturing facility in Belgium.